On October 25, 2010  The Servier Research Group and Vernalis reported they have achieved a research milestone in their three year oncology drug discovery collaboration initiated in May 2009 (Press release, Servier, OCT 25, 2010, View Source [SID:1234508828]). This is the second collaboration between Servier and Vernalis, the first collaboration is focused on developing two promising oncology targets involved in protein-protein interactions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Emmanuel Canet, MD, PhD, President Servier Research and Development, added: "We are very satisfied with this collaboration reaching an important milestone on a truly innovative oncology target. This is a step further in our aim to finalise the discovery of innovative compounds with potential use in therapeutic indications with high unmet medical need. Cancer represents a major cause of mortality worldwide and Servier is committed to providing patients with novel therapeutic approaches for treating this devastating disease.
Vernalis is an English biotech company which has a high-level technical background and recognised expertise in research and development.